IRIDEX Corporation (IRIX)
| Previous close | 2.6300 |
| Open | 2.6350 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.6301 - 2.7100 |
| 52-week range | 1.3100 - 3.6500 |
| Volume | |
| Avg. volume | 38,758 |
| Market cap | 43.233M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Iridex Reports First Quarter 2024 Financial Results
MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights Generated total revenue of $11.8 million, compared to $13.7 million in the prior year
- GlobeNewswire
Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. P
- GlobeNewswire
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
Advances strategic review to unlock shareholder valueMOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Gener
